Drug Profile
EP 51216
Latest Information Update: 07 Feb 2005
Price :
$50
*
At a glance
- Originator Ardana Bioscience
- Class
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Somatotropin deficiency
Most Recent Events
- 07 Feb 2005 No development reported - Phase-I for Somatotropin deficiency in France (PO)
- 25 Aug 2002 Europeptides has been acquired from Zentaris AG by Ardana Bioscience
- 14 May 2001 Phase-I clinical trials for Somatotropin deficiency in France (PO)